Blosozumab

Blosozumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	SOST
Clinical data
ATC code	none;
Identifiers
CAS Number	1132758-87-2 ;
ChemSpider	none;
UNII	83YOM0NEL5;
KEGG	D10094 ;
Chemical and physical data
Formula	C6462H9852N1684O2030S46
Molar mass	145086.42 g·mol−1
	(what is this?) (verify)

Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.^[1] Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.^[2]

Blosozumab was developed by Eli Lilly and Company.

References

^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).^{[dead link]}
^ McColm J, Hu L, Womack T, Tang CC, Chiang AY (April 2014). "Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women". Journal of Bone and Mineral Research. 29 (4): 935–43. doi:10.1002/jbmr.2092. PMID 23996473.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

[1] World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).^{[dead link]}

[2] McColm J, Hu L, Womack T, Tang CC, Chiang AY (April 2014). "Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women". Journal of Bone and Mineral Research. 29 (4): 935–43. doi:10.1002/jbmr.2092. PMID 23996473.

[1]

[2]